Sarclisa FDA Approval History
Last updated by Judith Stewart, BPharm on April 7, 2021.Sarclisa (isatuximab-irfc) is a CD38-directed cytolytic antibody indicated:
- in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor.
- in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.
Development timeline for Sarclisa
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.